Viewpoint
Abstract
Authors
Erik S. Musiek, Teresa Gomez-Isla, David M. Holtzman
Abstract
Authors
David Wendler, Seher Anjum, Peter Williamson
Abstract
Authors
Thomas O. Crawford, Charlotte J. Sumner
Abstract
Authors
Øystein Fluge, Karl J. Tronstad, Olav Mella
Abstract
Authors
James Meixiong, Sherita Hill Golden
Abstract
Authors
Giorgio Sirugo, Sarah A. Tishkoff, Scott M. Williams
Abstract
Authors
Allison T. McElvaine, Jacqueline A. Hawkins-Salsbury, Vineet M. Arora, Mark T. Gladwin, James R. Goldenring, David P. Huston, Deborah Krakow, Kyu Rhee, Julian Solway, Richard A. Steinman, Dwight A. Towler, Paul J. Utz, Wayne M. Yokoyama, Rolly L. Simpson, Louis J. Muglia, Sallie R. Permar, Rasheed A. Gbadegesin
Abstract
Recently there have been several reports of SARS-CoV2 “breakthrough” infections that have occurred in recipients of the FDA approved SAR-CoV-2 vaccines. The use of the term “breakthrough” infections implies that the virus broke through a protective barrier provided by the vaccine. However, is this what happened in these cases? In most cases, the answer is no, and this answer lies in the fundamental understanding of the mucosal immune system. Here we suggest a more precise definition of what a true breakthrough case is.
Authors
John S. Schieffelin, Elizabeth B. Norton, Jay K. Kolls
Abstract
Undeniably, a global and coordinated COVID-19 vaccination effort is a prerequisite for taming the spread of emerging SARS-CoV-2 variants and achieving population-wide immunity that can thwart future viral surges. However, rare vaccine-related adverse events were recently reported in individuals that received the adenoviral-encoded ChAdOx1 nCov-19 and Ad26.COV2.S vaccines. Here, we discuss the the potential contribution of complement activation to vaccine-related pathology.
Authors
Dimitrios C. Mastellos, Panagiotis Skendros, John D. Lambris
No posts were found with this tag.
Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)